165 related articles for article (PubMed ID: 32667731)
81. SPAG5: An Emerging Oncogene.
He J; Green AR; Li Y; Chan SYT; Liu DX
Trends Cancer; 2020 Jul; 6(7):543-547. PubMed ID: 32291236
[TBL] [Abstract][Full Text] [Related]
82. Inhibition of hypoxia-inducible factor 1 by acriflavine renders glioblastoma sensitive for photodynamic therapy.
Ma S; Wang F; Dong J; Wang N; Tao S; Du J; Hu S
J Photochem Photobiol B; 2022 Sep; 234():112537. PubMed ID: 35939916
[TBL] [Abstract][Full Text] [Related]
83. DNA topoisomerase inhibition with the HIF inhibitor acriflavine promotes transcription of lncRNAs in endothelial cells.
Seredinski S; Boos F; Günther S; Oo JA; Warwick T; Izquierdo Ponce J; Lillich FF; Proschak E; Knapp S; Gilsbach R; Pflüger-Müller B; Brandes RP; Leisegang MS
Mol Ther Nucleic Acids; 2022 Mar; 27():1023-1035. PubMed ID: 35228897
[TBL] [Abstract][Full Text] [Related]
84. Ultrastable Iodinated Oil-Based Pickering Emulsion Enables Locoregional Sustained Codelivery of Hypoxia Inducible Factor-1 Inhibitor and Anticancer Drugs for Tumor Combination Chemotherapy.
Li Z; Liu X; Xiao J; Jiang H; Ma L; Luo Y; Wang M; Zhu Y; Jiang H; Yao H; Ngai T; Guo Q
ACS Biomater Sci Eng; 2024 Apr; 10(4):2270-2281. PubMed ID: 38536862
[TBL] [Abstract][Full Text] [Related]
85. Leelamine Modulates STAT5 Pathway Causing Both Autophagy and Apoptosis in Chronic Myelogenous Leukemia Cells.
Jung YY; Um JY; Chinnathambi A; Govindasamy C; Sethi G; Ahn KS
Biology (Basel); 2022 Feb; 11(3):. PubMed ID: 35336740
[TBL] [Abstract][Full Text] [Related]
86. Retraction for Lee et al., Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization.
Proc Natl Acad Sci U S A; 2023 May; 120(18):e2305537120. PubMed ID: 37099630
[No Abstract] [Full Text] [Related]
87. THE ANTISEPTIC PROPERTIES OF ACRIFLAVINE AND PROFLAVINE, AND BRILLIANT GREEN: WITH SPECIAL REFERENCE TO SUITABILITY FOR WOUND THERAPY.
Browning CH; Gulbransen R; Thornton LH
Br Med J; 1917 Jul; 2(2951):70-5. PubMed ID: 20768664
[No Abstract] [Full Text] [Related]
88. THE CHEMOTHERAPY OF RECENT EXPERIMENTAL WOUND INFECTIONS: WITH SPECIAL REFERENCE TO THE ACTION OF ACRIFLAVINE.
Browning CH; Gulbransen R
Br Med J; 1925 Apr; 1(3354):688-90. PubMed ID: 20772003
[No Abstract] [Full Text] [Related]
89. Repurposing of Acriflavine to Target Chronic Myeloid Leukemia Treatment.
Nehme R; Hallal R; El Dor M; Kobeissy F; Gouilleux F; Mazurier F; Zibara K
Curr Med Chem; 2021; 28(11):2218-2233. PubMed ID: 32900342
[TBL] [Abstract][Full Text] [Related]
90. Acriflavine, a Potent Inhibitor of HIF-1α, Disturbs Glucose Metabolism and Suppresses ATF4-Protective Pathways in Melanoma under Non-Hypoxic Conditions.
Martí-Díaz R; Montenegro MF; Cabezas-Herrera J; Goding CR; Rodríguez-López JN; Sánchez-Del-Campo L
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396270
[TBL] [Abstract][Full Text] [Related]
91. Assessment of structural and activity-related contributions of various PIM-1 kinase inhibitors in the treatment of leukemia and prostate cancer.
Sharma A; Dubey R; Asati V; Baweja GS; Gupta S; Asati V
Mol Divers; 2024 Apr; ():. PubMed ID: 38642309
[TBL] [Abstract][Full Text] [Related]
92. Acriflavine, a HIF-1 inhibitor, preserves vision in an experimental autoimmune encephalomyelitis model of optic neuritis.
Anders JJ; Elwood BW; Kardon RH; Gramlich OW
Front Immunol; 2023; 14():1271118. PubMed ID: 37942317
[TBL] [Abstract][Full Text] [Related]
93. Application of Drug Repurposing-Based Precision Medicine Platform for Leukaemia Patient Treatment.
Kenmogne VL; Nweke EE; Takundwa MM; Fru PN; Thimiri Govinda Raj DB
Adv Exp Med Biol; 2023; 1410():115-126. PubMed ID: 36289161
[TBL] [Abstract][Full Text] [Related]
94. Acriflavine, an Acridine Derivative for Biomedical Application: Current State of the Art.
Piorecka K; Kurjata J; Stanczyk WA
J Med Chem; 2022 Sep; 65(17):11415-11432. PubMed ID: 36018000
[TBL] [Abstract][Full Text] [Related]
95. Targeting HIF-1α by Natural and Synthetic Compounds: A Promising Approach for Anti-Cancer Therapeutics Development.
Ghosh R; Samanta P; Sarkar R; Biswas S; Saha P; Hajra S; Bhowmik A
Molecules; 2022 Aug; 27(16):. PubMed ID: 36014432
[TBL] [Abstract][Full Text] [Related]
96. The Activation of the Tumor Suppressor Protein p53 by Acriflavine Leads to Mitochondrial Dysfunction and Improves the Radiosensitivity of Colon Cancer Cells.
Lin C; Chen X; Qiu H; Li B; Guo M
J Immunol Res; 2022; 2022():1328542. PubMed ID: 35935580
[TBL] [Abstract][Full Text] [Related]
97. Chronic myeloid leukemia stem cells: targeting therapeutic implications.
Mojtahedi H; Yazdanpanah N; Rezaei N
Stem Cell Res Ther; 2021 Dec; 12(1):603. PubMed ID: 34922630
[TBL] [Abstract][Full Text] [Related]
98. Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia.
Hammond D; Montalban-Bravo G
Curr Hematol Malig Rep; 2021 Oct; 16(5):405-417. PubMed ID: 34499330
[TBL] [Abstract][Full Text] [Related]
99. Acriflavine targets oncogenic STAT5 signaling in myeloid leukemia cells.
Hallal R; Nehme R; Brachet-Botineau M; Nehme A; Dakik H; Deynoux M; Dello Sbarba P; Levern Y; Zibara K; Gouilleux F; Mazurier F
J Cell Mol Med; 2020 Sep; 24(17):10052-10062. PubMed ID: 32667731
[TBL] [Abstract][Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
